Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zanzalintinib fumarate by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oral Cavity (Mouth) Cancer. According to...
Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Urethral Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Urethral Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Zanzalintinib fumarate by Exelixis for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Zanzalintinib fumarate by Exelixis for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Zanzalintinib fumarate by Exelixis for Ureter Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Ureter Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Zanzalintinib fumarate by Exelixis for Non-Small Cell Lung Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Zanzalintinib fumarate by Exelixis for Solid Tumor: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Bladder Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Zanzalintinib fumarate by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...